NASDAQ$AGEN

Agenus Inc · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Agenus reported a net loss despite revenue generation, with a significant reduction in operational costs and strategic initiatives to bolster its financial position.

Agenus reported Q4 2024 revenue of $26.8 million but incurred a net loss of $46.8 million. The company continued its cost-cutting strategy, reducing its operational burn rate and monetizing non-core assets. Significant progress was made in its BOT/BAL program, with external clinical trials validating its potential. The company also ended the year with $40.4 million in cash and cash equivalents.

  • Agenus generated $26.8 million in revenue for Q4 2024.
  • The company reported a net loss of $46.8 million, or $2.04 per share.
  • Significant cost-cutting measures reduced the operational burn rate.
  • BOT/BAL program demonstrated strong clinical validation in multiple oncology trials.

Headline financials

Total Revenue

$26.8M

Previous: $83.8M-68.0%
EPS (adj)

-$2.04

Previous: -$2.60+21.5%
Cash used in operations

$28.7M

No prior period
Net Income

-$46.8M

Previous: -$48.6M+3.7%
Operating Income

-$46.8M

Previous: -$4.36M-973.8%

Revenue & EPS history

Agenus · Revenue · Quarterly

$26.8M

Q4 2024-68%vs Q4 2023
Beat estimate in 6 of 15 quarters(40%)
ActualEstimate

Forward guidance

Agenus plans to further reduce costs while advancing its BOT/BAL program, with expectations to lower its operational burn to $50 million annually by mid-2025.

Tailwinds

  • Projected reduction in operational burn rate to $50 million annually by mid-2025.
  • Monetization of non-core assets expected to strengthen financial position.
  • Strong clinical validation of BOT/BAL program.
  • Continued discussions for potential partnerships and external funding.
  • Ongoing investigator-sponsored trials providing cost efficiencies.

Headwinds

  • Net losses continue despite revenue generation.
  • Declining cash reserves compared to the previous year.
  • Heavy reliance on external funding and strategic partnerships for BOT/BAL program.
  • Cost-cutting measures may impact future operational capabilities.
  • Uncertain market conditions affecting biotech sector valuations.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.7%

Avg return

Earnings day

+0.2%

Avg return

5 days after

+6.1%

Avg return

30 days after

49%

31 / 63 earnings

Positive

+39.9%

Q4 2011

Best reaction

-22.3%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-14.9%-6.3%
Q4 2025+5.8%+19.7%+55.8%
Q3 2025+6.3%+9.0%+2.8%
Q1 2025+20.3%+19.6%+77.3%
Q4 2024-4.7%-13.5%-24.7%
Q3 2024-22.3%-30.3%-21.0%
Q2 2024+0.2%-7.3%-2.6%
Q1 2024-11.4%-19.0%+27.9%
Q4 2023-18.0%-15.2%-38.3%
Q3 2023+7.5%-16.7%+3.8%
Q2 2023-5.9%-0.7%-7.4%
Q1 2023-3.1%-10.7%+28.3%
Q4 2022+10.5%-0.6%-12.3%
Q3 2022-15.5%+5.0%+5.0%
Q2 2022+2.3%+13.8%+0.4%
Q1 2022-0.7%+7.2%+7.9%
Q4 2021+13.7%+7.8%-8.9%
Q3 2021+3.6%-7.2%-23.2%
Q2 2021-0.4%+9.2%+13.0%
Q1 2021+4.2%+5.1%+36.6%
Q4 2020-3.0%-6.3%-18.7%
Q3 2020+0.0%+4.9%+0.5%
Q2 2020+12.3%+5.7%+17.4%
Q1 2020-4.2%-3.0%+45.8%
Q4 2019-7.4%-20.6%-8.1%
Q3 2019+13.3%+25.3%+38.2%
Q2 2019+17.8%+24.7%+41.6%
Q1 2019+7.5%+10.2%+1.5%
Q4 2018-3.0%+1.0%-12.2%
Q3 2018+10.1%+5.9%+25.0%
Q2 2018+4.6%+3.5%+16.8%
Q1 2018-14.1%-3.3%-14.4%
Q4 2017+2.1%-1.6%-18.7%
Q3 2017-4.4%+1.6%-1.4%
Q2 2017-2.4%-6.6%-9.7%
Q1 2017+10.5%+10.5%+2.3%
Q4 2016+3.9%+0.3%-14.9%
Q3 2016-21.8%-26.0%-7.1%
Q2 2016+12.6%+12.6%+26.2%
Q1 2016-16.2%
Q4 2015+19.6%
Q3 2015-5.4%
Q2 2015-7.4%
Q1 2015+17.1%
Q3 2014-2.9%
Q2 2014+6.2%
Q1 2014-5.2%
Q4 2013+0.4%
Q3 2013+2.8%
Q2 2013+1.0%
Q1 2013+1.1%
Q4 2012+4.6%
Q3 2012-7.2%
Q2 2012-4.2%
Q1 2011-3.9%
Q1 2012+6.7%
Q4 2011+39.9%
Q3 2011-3.7%
Q2 2011-16.2%
Q4 2010-4.0%
Q3 2010-5.2%
Q2 2010-1.2%
Q1 2010+14.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro